Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+/HER2- Advanced Breast Cancer
HC Wainwright & Co. Reiterates Buy on Faeth Therapeutics, Maintains $60 Price Target
Faeth Therapeutics Enters Into Clinical Trial Collaboration And Supply Agreement With Roche To Evaluate PIKTOR In Combination With Investigational Medicine Giredestrant In Patients With HR+/HER2- Advanced Breast Cancer
Faeth Therapeutics to Participate in Upcoming November Investor Conferences
Citigroup Maintains Buy on Faeth Therapeutics, Raises Price Target to $60
Faeth selloff ‘disproportionate’ to data, says Lucid Capital
Faeth Therapeutics Plummets 42%. What Investors Are Getting Wrong, According To Analysts.
Faeth Therapeutics Reports 33% Response Rate in Phase 2 PIKTOR Trial for Advanced Endometrial Cancer
Faeth Therapeutics reports positive Phase 2 results for endometrial cancer drug
Faeth Reports Positive Preliminary Phase 2 Topline Results from the PIK-201 Trial Evaluating PIKTOR in Combination with Paclitaxel in Patients with Advanced Endometrial Cancer
Faeth Therapeutics Announces Data From Its Phase 2 Study Of PIKTOR Shows Confirmed Objective Response Rate OF 33%, Disease Control Rate Of 83%
Faeth to Report PIK-201 Phase 2 Data and Host Virtual Event on November 9, 2026
Faeth Therapeutics To Conduct Virtual Event On Nov. 9 To Present Topline Data From Its Phase 2 PIK-2-1 Study Of PIKTOR To Treat Endometrial Cancer
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Analyst Firms Have Faith In Faeth Therapeutics
Guggenheim Maintains Buy on Faeth Therapeutics, Lowers Price Target to $69
Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational Updates
Faeth Therapeutics Q3 EPS $(0.79) Misses $(0.71) Estimate
Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors
BTIG Reiterates Buy on Faeth Therapeutics, Maintains $55 Price Target
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.